No headlines found.
No press releases found.
No news found.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Impact Biomedical trades on the AMEX stock market under the symbol IBO.
As of August 28, 2026, IBO stock price was flat at $0.44 with 6,540 million shares trading.
IBO has a beta of -0.64, meaning it tends to be less sensitive to market movements. IBO has a correlation of 0.01 to the broad based SPY ETF.
IBO has a market cap of $47.84 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that IBO belongs to (by Net Assets): VXF, ITOT.
IBO has underperformed the market in the last year with a price return of -24.5% while the SPY ETF gained +19.7%. IBO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and -3.4%, respectively, while the SPY returned +2.2% and -0.9%, respectively.
IBO support price is $.42 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBO shares will trade within this expected range on the day.
